Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1926MR)

This product GTTS-WQ1926MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species synthetic construct
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1926MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7502MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ8024MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ709MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA A-623
GTTS-WQ689MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ10123MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LAG-525
GTTS-WQ15793MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ6071MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ8267MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HM10560A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW